DAX23.092 -0,8%Est505.515 -1,0%MSCI World4.343 -0,1%Top 10 Crypto11,60 -4,3%Nas22.359 +1,3%Bitcoin72.659 -3,3%Euro1,1513 -0,1%Öl62,47 -1,1%Gold4.060 -0,4%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 RENK RENK73 DroneShield A2DMAA Siemens Energy ENER6Y Deutsche Telekom 555750 Amazon 906866 Tesla A1CX3T Infineon 623100 Lufthansa 823212 Alphabet A (ex Google) A14Y6F TKMS thyssenkrupp Marine Systems TKMS00 Palantir A2QA4J SAP 716460 Siemens 723610
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX geht bei über 23.000 Punkten ins Wochenende -- Wall Street steigt -- Portfolio von NVIDIA -- Bitcoin & Co. tiefrot -- D-Wave, Novo Nordisk, Siemens Energy, DroneShield, Rheinmetall, RENK im Fokus
Top News
Top-News der Woche: Diese Themen waren diese Woche wichtig Top-News der Woche: Diese Themen waren diese Woche wichtig
23.000-Punkte-Marke knapp gehalten: DAX geht mit Verlusten ins Wochenende - NVIDIA-Rally verpufft schneller als gedacht 23.000-Punkte-Marke knapp gehalten: DAX geht mit Verlusten ins Wochenende - NVIDIA-Rally verpufft schneller als gedacht
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Für alle, die mehr wollen: Bonus-Zertifikate der LBBW. Jetzt mehr erfahren!

Biohaven Research Aktie

Kaufen
Verkaufen
8,65 EUR +0,35 EUR +4,22 %
BER
9,76 USD +0,12 USD +1,24 %
BTT
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.867,23 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA3DVH7

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINVGG1110E1079

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolBHVN

Biohaven Research Aktien News

DatumMeistgelesen
PR NewswireBiohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300
PR NewswireBiohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results
PR NewswireBiohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia
PR NewswireBiohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective ...
PR NewswireBiohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PR NewswireBiohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other K...
PR NewswireBiohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting
PR NewswireBiohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity
PR NewswireBiohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments
PR NewswireBiohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine
PR NewswireBiohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)
PR NewswireBiohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia
PR NewswireBiohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments
PR NewswireBiohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day
PR NewswireBiohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
PR NewswireBiohaven Reports First Quarter 2024 Financial Results and Recent Business Developments
PR NewswireBiohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates
PR NewswireBiohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
PR NewswireBiohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Th...
PR NewswireBiohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PR NewswireBiohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting
PR NewswireBiohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments
PR NewswireBiohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®
PR NewswireBiohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy
PR NewswireBiohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal...
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
PR NewswireBiohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy
PR NewswireBiohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments
PR NewswireBiohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate Updates
PR NewswireBiohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day
PR NewswireBiohaven to Present R&D Day at Yale School of Management
PR NewswireBiohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments
PR NewswireBiohaven Expands Executive Leadership Team with Appointment of Nick Kozauer M.D. as Senior Vice President for Clinical Development and Regulatory Strategy
PR NewswireBiohaven Reports Fourth Quarter and Full Year 2022 Financial Results and Reports Recent Business Developments
PR NewswireBiohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders
PR NewswireBiohaven Announces Presentation at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting
PR NewswireBiohaven's Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy
PR NewswireBiohaven to Present at the 41st Annual J.P. Morgan Healthcare Conference

Biohaven Research News

Biohaven Research News: auf dieser Seite finden Sie alle Biohaven Research News und Nachrichten zur Biohaven Research Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Biohaven Research News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Biohaven Research News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.